Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Keratosis, Actinic 1

Interventions

pembrolizumab 3enzalutamide 3Abiraterone Acetate 3apalutamide 2Topotecan 2Testosterone 2Itraconazole 2Docetaxel 2Cholecalciferol 2Celecoxib 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2zanubrutinib 1venetoclax 1talabostat 1sargramostim 1pasireotide 1olaparib 1leucoselect phytosome 1ibrutinib 1capivasertib 1acalabrutinib 1abiraterone 1Tablets 1Streptozocin 1Rituximab 1Radiosurgery 1Pluvicto 1PT-100 dipeptide 1Oxaliplatin 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × FED × Imipramine × Clear all
NCT06778434 2025-12-22

The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans

VA Office of Research and Development

Phase 2 Recruiting
48 enrolled
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡